Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.

Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS, Wong F, Azad NS, Rucki AA, Laheru D, Donehower R, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Greten TF, Duffy AG, Ciombor KK, Eyring AD, Lam BH, Joe A, Kang SP, Holdhoff M, Danilova L, Cope L, Meyer C, Zhou S, Goldberg RM, Armstrong DK, Bever KM, Fader AN, Taube J, Housseau F, Spetzler D, Xiao N, Pardoll DM, Papadopoulos N, Kinzler KW, Eshleman JR, Vogelstein B, Anders RA, Diaz LA Jr.

Science. 2017 Jul 28;357(6349):409-413. doi: 10.1126/science.aan6733. Epub 2017 Jun 8.

2.

Immunotherapy holds the key to cancer treatment and prevention in constitutional mismatch repair deficiency (CMMRD) syndrome.

Westdorp H, Kolders S, Hoogerbrugge N, de Vries IJM, Jongmans MCJ, Schreibelt G.

Cancer Lett. 2017 Sep 10;403:159-164. doi: 10.1016/j.canlet.2017.06.018. Epub 2017 Jun 20. Review.

3.

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.

Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Duffy SM, Goldberg RM, de la Chapelle A, Koshiji M, Bhaijee F, Huebner T, Hruban RH, Wood LD, Cuka N, Pardoll DM, Papadopoulos N, Kinzler KW, Zhou S, Cornish TC, Taube JM, Anders RA, Eshleman JR, Vogelstein B, Diaz LA Jr.

N Engl J Med. 2015 Jun 25;372(26):2509-20. doi: 10.1056/NEJMoa1500596. Epub 2015 May 30.

4.

Hypermutated Tumors and Immune Checkpoint Inhibition.

Ciombor KK, Goldberg RM.

Drugs. 2018 Feb;78(2):155-162. doi: 10.1007/s40265-018-0863-0. Review.

PMID:
29350327
5.

MMR deficiency may lead to a high immunogenicity and then an improvement in anti-PD-1 efficacy for metastatic colorectal cancer.

Aguiar PN Jr, Tadokoro H, Forones NM, de Mello RA.

Immunotherapy. 2015;7(11):1133-4. doi: 10.2217/imt.15.84. Epub 2015 Nov 16. Review. No abstract available.

PMID:
26568256
6.

PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors.

Sloan EA, Ring KL, Willis BC, Modesitt SC, Mills AM.

Am J Surg Pathol. 2017 Mar;41(3):326-333. doi: 10.1097/PAS.0000000000000783.

PMID:
27984238
7.

Successful immune checkpoint blockade in a patient with advanced stage microsatellite-unstable biliary tract cancer.

Czink E, Kloor M, Goeppert B, Fröhling S, Uhrig S, Weber TF, Meinel J, Sutter C, Weiss KH, Schirmacher P, Doeberitz MVK, Jäger D, Springfeld C.

Cold Spring Harb Mol Case Stud. 2017 Sep 1;3(5). pii: a001974. doi: 10.1101/mcs.a001974. Print 2017 Sep.

8.

Programmed death 1 blockade, an Achilles heel for MMR-deficient tumors?

Lin AY, Lin E.

J Hematol Oncol. 2015 Nov 5;8:124. doi: 10.1186/s13045-015-0222-5.

9.

Upper gastrointestinal malignancies in 2017: current perspectives and future approaches.

Solomon BL, Garrido-Laguna I.

Future Oncol. 2018 Apr;14(10):947-962. doi: 10.2217/fon-2017-0597. Epub 2018 Mar 15. Review.

10.

Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency.

Bouffet E, Larouche V, Campbell BB, Merico D, de Borja R, Aronson M, Durno C, Krueger J, Cabric V, Ramaswamy V, Zhukova N, Mason G, Farah R, Afzal S, Yalon M, Rechavi G, Magimairajan V, Walsh MF, Constantini S, Dvir R, Elhasid R, Reddy A, Osborn M, Sullivan M, Hansford J, Dodgshun A, Klauber-Demore N, Peterson L, Patel S, Lindhorst S, Atkinson J, Cohen Z, Laframboise R, Dirks P, Taylor M, Malkin D, Albrecht S, Dudley RW, Jabado N, Hawkins CE, Shlien A, Tabori U.

J Clin Oncol. 2016 Jul 1;34(19):2206-11. doi: 10.1200/JCO.2016.66.6552. Epub 2016 Mar 21.

PMID:
27001570
11.

Mismatch repair deficiency is associated with MSI phenotype, increased tumor-infiltrating lymphocytes and PD-L1 expression in immune cells in ovarian cancer.

Xiao X, Dong D, He W, Song L, Wang Q, Yue J, Xie L.

Gynecol Oncol. 2018 Apr;149(1):146-154. doi: 10.1016/j.ygyno.2018.02.009. Epub 2018 Mar 1.

PMID:
29496294
12.

Somatic mutations of the coding microsatellites within the beta-2-microglobulin gene in mismatch repair-deficient colorectal cancers and adenomas.

Clendenning M, Huang A, Jayasekara H, Lorans M, Preston S, O'Callaghan N, Pope BJ, Macrae FA, Winship IM, Milne RL, Giles GG, English DR, Hopper JL, Win AK, Jenkins MA, Southey MC, Rosty C, Buchanan DD; investigators from the Melbourne Collaborative Cohort Study and the Australasian Colorectal Cancer Family Registry Cohort.

Fam Cancer. 2018 Jan;17(1):91-100. doi: 10.1007/s10689-017-0013-y.

13.

Patterns and prognostic relevance of PD-1 and PD-L1 expression in colorectal carcinoma.

Lee LH, Cavalcanti MS, Segal NH, Hechtman JF, Weiser MR, Smith JJ, Garcia-Aguilar J, Sadot E, Ntiamoah P, Markowitz AJ, Shike M, Stadler ZK, Vakiani E, Klimstra DS, Shia J.

Mod Pathol. 2016 Nov;29(11):1433-1442. doi: 10.1038/modpathol.2016.139. Epub 2016 Jul 22.

14.

Rapid disease progression in a patient with mismatch repair-deficient and cortisol secreting adrenocortical carcinoma treated with pembrolizumab.

Casey RT, Giger O, Seetho I, Marker A, Pitfield D, Boyle LH, Gurnell M, Shaw A, Tischkowitz M, Maher ER, Chatterjee VK, Janowitz T, Mells G, Corrie P, Challis BG.

Semin Oncol. 2018 Jun;45(3):151-155. doi: 10.1053/j.seminoncol.2018.06.001. Epub 2018 Jun 21.

15.

Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells.

Le Flahec G, Badic B, Guibourg B, Doucet L, Bail JP, Marcorelles P, Schick U, Uguen A.

Hum Pathol. 2018 Feb;72:135-143. doi: 10.1016/j.humpath.2017.09.019. Epub 2017 Dec 5.

PMID:
29208565
16.

Efficacy of PD-1 blockade in tumors with MMR deficiency.

Lee V, Le DT.

Immunotherapy. 2016;8(1):1-3. doi: 10.2217/imt.15.97. Epub 2015 Dec 8. No abstract available.

17.

Mismatch Repair Deficiency and Response to Immune Checkpoint Blockade.

Lee V, Murphy A, Le DT, Diaz LA Jr.

Oncologist. 2016 Oct;21(10):1200-1211. Epub 2016 Jul 13. Review.

18.

Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer.

Anagnostou V, Smith KN, Forde PM, Niknafs N, Bhattacharya R, White J, Zhang T, Adleff V, Phallen J, Wali N, Hruban C, Guthrie VB, Rodgers K, Naidoo J, Kang H, Sharfman W, Georgiades C, Verde F, Illei P, Li QK, Gabrielson E, Brock MV, Zahnow CA, Baylin SB, Scharpf RB, Brahmer JR, Karchin R, Pardoll DM, Velculescu VE.

Cancer Discov. 2017 Mar;7(3):264-276. doi: 10.1158/2159-8290.CD-16-0828. Epub 2016 Dec 28.

19.

Mismatch repair deficiency is a rare but putative therapeutically relevant finding in non-liver fluke associated cholangiocarcinoma.

Goeppert B, Roessler S, Renner M, Singer S, Mehrabi A, Vogel MN, Pathil A, Czink E, Köhler B, Springfeld C, Pfeiffenberger J, Rupp C, Weiss KH, Schirmacher P, von Knebel Doeberitz M, Kloor M.

Br J Cancer. 2019 Jan;120(1):109-114. doi: 10.1038/s41416-018-0199-2. Epub 2018 Oct 31.

PMID:
30377340
20.

Cancer Drugs Approved Based on Biomarkers and Not Tumor Type-FDA Approval of Pembrolizumab for Mismatch Repair-Deficient Solid Cancers.

Prasad V, Kaestner V, Mailankody S.

JAMA Oncol. 2018 Feb 1;4(2):157-158. doi: 10.1001/jamaoncol.2017.4182. No abstract available. Erratum in: JAMA Oncol. 2018 Oct 1;4(10):1439.

PMID:
29285544

Supplemental Content

Support Center